Cargando…
Analgesic and anti‐inflammatory properties of novel, selective, and potent EP4 receptor antagonists
Prostaglandin (PG) E(2) is the key driver of inflammation associated with arthritic conditions. Inhibitors of PGE (2) production (NSAIDs and Coxibs) are used to treat these conditions, but carry significant side effect risks due to the inhibition of all prostanoids that play important physiological...
Autores principales: | Chandrasekhar, Srinivasan, Yu, Xiao‐Peng, Harvey, Anita K., Oskins, Jennifer L., Lin, Chaohua, Wang, Xushan, Blanco, Maria‐Jesus, Fisher, Matthew J., Kuklish, Steven L., Schiffler, Matthew A., Vetman, Tatiana, Warshawsky, Alan M., York, Jeremy S., Bendele, Alison M., Chambers, Mark G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464344/ https://www.ncbi.nlm.nih.gov/pubmed/28603634 http://dx.doi.org/10.1002/prp2.316 |
Ejemplares similares
-
The Analgesic Activity of Bestatin as a Potent APN Inhibitor
por: Jia, Mei-Rong, et al.
Publicado: (2010) -
Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists
por: Bödder, Johanna, et al.
Publicado: (2023) -
Lead Optimization Studies of Cinnamic Amide EP2 Antagonists
por: Ganesh, Thota, et al.
Publicado: (2014) -
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
por: Reynaert, Marie-Line, et al.
Publicado: (2019) -
Buprenorphine in rats: potent analgesic or trigger for fatal side effects?
por: Reifenrath, Janin, et al.
Publicado: (2022)